Press release
Atopic Dermatitis Drugs Market Revenue Analysis, Industry Outlook, Forecast, 2019-2032
The global market for atopic dermatitis drugs, valued at USD 6.10 billion in 2022, is projected to expand significantly with a rapid compound annual growth rate (CAGR) of 15.2% over the coming years. This growth is largely driven by the increasing prevalence of atopic dermatitis, a chronic inflammatory skin condition affecting approximately 10% to 30% of children and 2% to 10% of adults in developed nations. Enhanced awareness and expanded treatment options are expected to support this trajectory, according to recent findings.
Request a Sample Report with Table of Contents and Figures to click Here: https://www.emergenresearch.com/request-sample/2588
Key Drivers for Market Expansion
A major factor supporting growth is the approval of innovative drugs targeting specific proteins associated with atopic dermatitis, including inhibitors of IL-4, IL-13, IL-31, and Thymic Stromal Lymphopoietin (TSLP). In October 2023, for instance, the FDA approved Arcutis Biotherapeutics' Zoryve cream for treating plaque psoriasis in children, reflecting regulatory support for new drugs in dermatology.
Moreover, robust investment in research and development (R&D) is accelerating drug discovery and approval. In 2023, the National Eczema Association (NEA) committed up to USD 100,000 in research grants to support innovation. The market is seeing the development of over 70 new compounds, including oral medications designed specifically to meet the needs of those affected by atopic dermatitis. Rising product approvals, especially of biologics, are anticipated to drive continued revenue growth.
Market Challenges
However, certain factors may restrict the market's full potential. The high cost of atopic dermatitis treatment in some regions limits access, while some drugs carry side effects that could hinder long-term usage, particularly in children and patients with severe cases. Additionally, allergic reactions to certain therapies and the expiration of product patents pose challenges for sustainable market growth.
Product Insights
The market is divided into segments based on product types, including biologics, calcineurin inhibitors, PDE-4 inhibitors, and corticosteroids. Among these, biologics held the largest revenue share in 2022, driven by consumer awareness of skin health and personal care. These advanced therapies offer promising efficacy, making them popular choices for patients dealing with recurring symptoms. The calcineurin inhibitors segment is also anticipated to grow steadily, due to factors such as increasing organ transplant cases and growing awareness about autoimmune conditions.
Mode of Administration Insights
The market is further segmented by mode of administration: topical, injectable, and oral. Injectable biologics, which include options like tofacitinib and ruxolitinib currently in clinical trials, are expected to dominate the market. These options are proving effective for pediatric patients, and ongoing R&D efforts aim to enhance treatment options for children. Meanwhile, the oral segment is also expected to grow as novel therapeutic targets emerge from recent advancements in disease mechanism research. Oral drugs are typically reserved for severe cases or for patients who have not responded well to other treatments.
For More Details On this Report Click Here @ https://www.emergenresearch.com/industry-report/atopic-dermatitis-drugs-market
End-Use Insights
End-use segments in the market include hospitals, retail, and online pharmacies. Hospital pharmacies are expected to account for the largest market share, supported by a rise in demand for prescription-based atopic dermatitis treatments. Governments are also working to strengthen hospital and pharmacy infrastructures, which will further boost this segment. The retail pharmacy sector is predicted to see the fastest growth, as policies continue to improve patient access to medications, and demand for non-prescription treatments rises.
As the atopic dermatitis drugs market evolves with ongoing R&D, innovative therapies, and regulatory support, significant growth is expected over the forecast period. For more information on market insights and emerging trends in atopic dermatitis treatment
To Customized Report Market: @ https://www.emergenresearch.com/request-for-customization/2588
Atopic Dermatitis Drugs Top Companies and Competitive Landscape
The global atopic dermatitis drugs market is fairly fragmented with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective atopic dermatitis drugs solutions.
Some major players included in the global atopic dermatitis drugs market report are:
Sanofi
Incyte
Pfizer Inc.
AbbVie Inc.
LEO Pharma
Teva Pharmaceutical Industries Ltd.
GALDERMA
Allergan India Private Limited
Bristol-Myers Squibb Company
Meda Pharmaceuticals
Regeneron Pharmaceuticals Inc
Atopic Dermatitis Drugs Latest Industry Updates
On 13 September 2023, Arcutis Biotherapeutics, submitted a supplemental new drug application to the Food and Drug Administration (FDA) for its roflumilast cream, which is approved for atopic dermatitis in patients aged 6 and older. The cream, also known as Zoryve, treats plaque psoriasis in the U.S.
On 24 August 2021, AbbVie, The European Commission, a prominent developing region in Atopic Dermatitis market, approved RINVOQ as the first JAK inhibitor in the European Union for treating moderate to severe atopic dermatitis in adults and adolescents. The approval is based on data from a Phase 3 program evaluating RINVOQ monotherapy or with topical corticosteroids, showing rapid improvement in skin clearance and itch reduction.
Atopic Dermatitis Drugs Market Segmentation Analysis
For the purpose of this report, Emergen Research has segmented the global atopic dermatitis drugs market on the basis of product, mode of administration, end-use, and region:
Product Outlook (Revenue, USD Billion; 2019-2032)
Biologics
Calcineurin Inhibitors
PDE-4 Inhibitors
Corticosteroids
Others
Mode of Administration Outlook (Revenue, USD Billion; 2019-2032)
Topical
Injectable
Oral
End-use Outlook (Revenue, USD Billion; 2019-2032)
Hospital
Retail
Online
Regional Outlook (Revenue, USD Billion; 2019-2032)
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Benelux
Russia
Rest of Europe
Asia Pacific
China
Japan
South Korea
India
ASEAN Countries
Oceania
Rest of APAC
Latin America
Brazil
Mexico
Rest of LATAM
Middle East & Africa
GCC Countries
Israel
Turkey
South Africa
Rest of Middle East & Africa
View Additional Related Reports:
Atopic Dermatitis Drugs Regional Market Demand: https://www.emergenresearch.com/industry-report/atopic-dermatitis-drugs-market/regional-market-demand
Atopic Dermatitis Drugs Market Analysis: https://www.emergenresearch.com/industry-report/atopic-dermatitis-drugs-market/market-analysis
Atopic Dermatitis Drugs Market Top Companies: https://www.emergenresearch.com/industry-report/atopic-dermatitis-drugs-market/top-companies
About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Drugs Market Revenue Analysis, Industry Outlook, Forecast, 2019-2032 here
News-ID: 3711906 • Views: …
More Releases from Emergen Research
Global Internet of Things (IoT) in Healthcare Market to Reach USD 299.05 Billion …
The global Internet of Things (IoT) in Healthcare Market was valued at USD 299.05 billion in 2023 and is expected to grow at a CAGR of 16.5% during the forecast period. This growth is fueled by the rising use of connected healthcare devices, increasing demand for early disease detection through remote monitoring, and growing adoption of artificial intelligence (AI) tools within IoT-based healthcare systems.
The market is also benefiting from the…
Global Stem Cell Therapy Market to Reach USD 49.2 Billion by 2034, Growing at 13 …
The global Stem Cell Therapy Market, valued at USD 13.7 billion in 2024, is projected to reach USD 49.2 billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.6%. Growth is being fueled by the rising burden of chronic diseases, rapid progress in cell-based studies, and increasing investments in regenerative medicine and personalized healthcare solutions.
Stem cell therapies offer the ability to repair, replace, or restore damaged tissues…
Artificial Intelligence Strengthens Cybersecurity as Threats Grow More Sophistic …
The global Artificial Intelligence in cybersecurity market size was USD 23.8 Billion in 2023 and is expected to reach a market valuation of USD 29.44 billion by the end of 2024 registering a CAGR of 23.7% during the forecast period. The adoption of Artificial Intelligence (AI) in cybersecurity is rapidly gaining traction as organizations worldwide face increasingly complex and frequent cyber threats. By combining advanced technologies such as Machine Learning…
Global Regenerative Medicine Market to Reach USD 125.6 Billion by 2034, Growing …
The global regenerative medicine market, valued at USD 34.2 billion in 2024, is set to grow to USD 125.6 billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.9%. Growth is being fueled by rising approvals of advanced therapies, strong demand for personalized treatments in cancer and orthopedics, and expanding cell and gene therapy manufacturing across major markets such as North America, Europe, and Asia.
Once seen as…
More Releases for Atopic
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
Atopic Dermatitis (Atopic Eczema) Treatment Market Business Growth And Industry …
Precision Business Insights published a research report on “Atopic Dermatitis (Atopic Eczema) Treatment Market by Drug type (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Phosphodiesterase type 4 (PDE-4) Inhibitors, Antibiotics, Antihistamines, Emollients), Route of administration (Oral, Topical, Parenteral), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography - Global/Region/Country Forecast to 2027”.
In people who suffer from atopic dermatitis, allergies play a big influence. When the patient is exposed to…
